# Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.

> PubMed lists PMID 26981947 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2016-03-17 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-26981947-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-01-03
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-26981947-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-26981947-lixisenatide-v1.json
- Content SHA-256: `ca37b8788440ae43b70d0fbd07e4c1eb08093d62fd286fcd6779c05c94a93536`

## Claims and source pins

### Headline

Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. ([`pubmed-observation-pmid-26981947-2025-01-03-d47f0ab7f825`](#source-pubmed-observation-pmid-26981947-2025-01-03-d47f0ab7f825))

### Summary

PubMed lists PMID 26981947 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2016-03-17 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26981947-2025-01-03-d47f0ab7f825`](#source-pubmed-observation-pmid-26981947-2025-01-03-d47f0ab7f825))

### Paragraph 1

PubMed lists PMID 26981947 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2016-03-17 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26981947-2025-01-03-d47f0ab7f825`](#source-pubmed-observation-pmid-26981947-2025-01-03-d47f0ab7f825))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-26981947-2025-01-03-d47f0ab7f825`](#source-pubmed-observation-pmid-26981947-2025-01-03-d47f0ab7f825))

## Sources

<a id="source-pubmed-observation-pmid-26981947-2025-01-03-d47f0ab7f825"></a>
- **Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. · retained source version 1:2025-01-03:current:d47f0ab7f8255c56112d27b8a878950727a863add0f76bce92c171584f9e8b9c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/26981947/) (`pubmed-observation-pmid-26981947-2025-01-03-d47f0ab7f825`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-26981947-lixisenatide-v1.json SHA-256: ca37b8788440ae43b70d0fbd07e4c1eb08093d62fd286fcd6779c05c94a93536.